Navigation Links
Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10
Date:10/11/2011

LONDON, October 12, 2011 /PRNewswire/ --

- Two pivotal trials initiated for treatment of iron deficiency anaemia associated with ulcerative colitis and Crohn's disease -

Shield Therapeutics (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need, today announced that the first patients have been treated in the two Phase 3 clinical studies of ST10 for the treatment of iron deficiency anaemia (IDA) in subjects with inflammatory bowel disease (IBD).

"Following our successful fundraising in June, we are delighted to have now treated the first patients in the AEGIS Phase 3 programme and we remain on course to have top line results from these studies in late 2012.  Effective treatment of IDA represents a very attractive commercial opportunity and the start of recruitment is an important milestone for Shield Therapeutics as we continue the rapid development of ST10 to address this significant unmet need for the many patients with IDA." said Carl Sterritt, Chief Executive Officer and Co-Founder of Shield Therapeutics.

ST10 is an oral ferric iron-based pharmaceutical that can be administered to patients with improved tolerability compared to currently marketed oral iron treatments and also does not carry the risk of hypersensitivity reactions as is the case with currently marketed intravenous iron therapies.  Whilst prescribers often try oral ferrous products as first line therapy, many subjects prove intolerant and suffer from continuously occurring side effects, exacerbation of inflammatory lesions and failure to correct iron deficiency.  This results in the need for expensive, complicated and invasive intravenous iron therapy.  When treated with ST10, the total dose exposure of unabsorbed iron within the gastrointestinal tr
'/>"/>

SOURCE Shield Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cord Blood America Enters Agreement With Regence, Serving BlueCross and BlueShield Programs in the Northwest U.S. and Mountain Regions
2. TCT 2009 to Feature vProtect(TM) Luminal Shield, a Novel Treatment Designed for Soft Coronary Lesions from Prescient Medical
3. vProtect(TM) Luminal Shield Stabilizes Life-Threatening Plaque
4. SyntheMed Announces FDA Clearance of SinusShield(TM)
5. NanoVibronix Receives FDA Clearance for its PainShield(TM) MD Device
6. United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program
7. United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
8. Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology
9. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
10. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
11. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... , Feb. 26, 2015 Tauriga Sciences, Inc. ... company with interests in the natural wellness sector and ... today that its products will be featured at the ... Partners, 27 th Annual Growth Stock Conference on ... at 1 Ritz Carlton Drive, Dana Point ...
(Date:2/26/2015)... 2015 CytomX, a biotechnology company developing Probody™ ... Sean McCarthy , D. Phil., chief executive officer, ... and Company 35 th Annual Health Care Conference ... will take place at 4 p.m. EST on Monday, ... Therapeutics develops Probody™ therapeutics for the treatment of cancer. ...
(Date:2/25/2015)... , Feb. 25, 2015 /CNW/ - Radient Technologies Inc. (TSX-V: ... its financial results for the third quarter of its ... statements, Management,s Discussion and Analysis, and the CEO & ... ended December 31, 2014 are available on ... CFO Appointment The Corporation is also pleased to announce ...
(Date:2/25/2015)... Market Publishers Ltd is happy to ... 9Dimen Research have been recently uploaded to its catalogue. ... Research Report . This research report provides wealth of ... world adhesive mortar industry as well as includes an ... regional markets. It focuses on the main regions such ...
Breaking Biology Technology:SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 2SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 3SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 4Radient Technologies Inc. Releases Third Quarter Results and Appoints New Interim CFO 2New Research Studies by 9Dimen Research Now Available at MarketPublishers.com 2New Research Studies by 9Dimen Research Now Available at MarketPublishers.com 3New Research Studies by 9Dimen Research Now Available at MarketPublishers.com 4
... Feb. 8 PharmAthene, Inc., a,biodefense company ... announced today that it has appointed Joan ... Dr. Fusco brings more than twenty years ... with broad experience in a variety of,functional ...
... in Spanish . , ANN ARBOR, Mich.---A ... walking to operate a portable GPS locator, a cell ... research involving the University of Michigan shows. , A ... 8 issue of the journal Science. Authors include researchers ...
... LifeCell Corporation,(Nasdaq: LIFC ), today announced revised preliminary ... final settlement of a claim that arose in,2007. The ... reduce,diluted net income per share by approximately $0.03. "Although ... the Company,s 2007,financial statements were not yet filed with ...
Cached Biology Technology:PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations 2PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations 3Knee brace generates electricity from walking 2LifeCell Corporation Revises Full Year 2007 Preliminary Results and Schedules Fourth Quarter 2007 Financial Results Conference Call; February 27, 2008 at 10:00 a.m. Eastern 2
(Date:2/5/2015)... New Market Research Reports Title ... To 2020 has Been Added to GrandViewReseach.com Report Database ... to reach USD 5.10 billion by 2020, according to ... cameras help identify the site of tissue damage in ... demand in medical imaging applications. They have been extensively ...
(Date:1/22/2015)... Jan. 22, 2015 Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ... A Global Market Overview" report to their offering. ... to ensure that an individual is who she/he is claiming ... use of a person,s unique physical characteristics, such as fingerprint, ...
(Date:1/22/2015)...  BellBrook Labs, a leader in high throughput screening ... a TR-FRET (time resolved Forster resonance energy transfer) ... high throughput screening assay for glycosyltransferases and other ... sensitive detection of hundreds of human and microbial ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... who are overweight or obese can encounter a host of ... their children grow and develop, at least initially. In ... , a team led by a University of Iowa researcher ... and obese mothers with those born to normal-weight mothers. ...
... are in everything from ocean currents to a flower,s petal. ... studying the biodiversity of yard plants in the U.S. and ... bees live on the Tibetan plateau and how willow trees ... that ecology, the study of relationships between living organisms and ...
... (ICSSR) in association with the Deutsche For-schungsgemeinschaft (DFG, ... la Recherche (ANR), the UKEconomic and Social Research ... (NWO) have launched the first set of projects ... researchers in India and the four European countries. ...
Cached Biology News:Infants of overweight mothers grow more slowly 2Infants of overweight mothers grow more slowly 3Tale of 2 scientific fields -- ecology and phylogenetics -- offers new views of Earth's biodiversity 2Tale of 2 scientific fields -- ecology and phylogenetics -- offers new views of Earth's biodiversity 3First Indian-European research networking projects in the social sciences launched 2First Indian-European research networking projects in the social sciences launched 3First Indian-European research networking projects in the social sciences launched 4
... Tfi DNA Ligase catalyzes the formation ... and 5-phosphate termini in nicked duplex DNA ... duplex with a complementary strand at 45 ... and active at much higher temperatures than ...
RABBIT ANTI RHEB (IN) Immunogen: A 15 amino acid peptide located in the central region of human Rheb....
Rabbit polyclonal antibody to Neuromedin U Receptor 1 (GPR66)...
... sheer in-house demand is causing shortages in your ... This can cause unwanted distractions, problems and delays. ... your hard work and endeavour! Bring us your ... market it internationally. We work under ISO 9001 ...
Biology Products: